Overview

Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need.

Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe and has demonstrated the potential to treat multiple severe and life-threatening fibro-inflammatory diseases.

Chemomab has reported positive results from three clinical trials of CM-101 completed to date. A Phase 2 trial in the rare liver disease primary sclerosing cholangitis (PSC) has completed patient enrollment, with topline data expected midyear 2024.

Recent News
Mar 7, 2024

─Accelerated Phase 2 CM-101 PSC Trial Timeline with Topline 15-Week Data Now Planned for Midyear 2024 and Topline Open Label Data Expected in Late 2024/Early 2025─ ─Cash Runway Extended...

Mar 5, 2024

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today...

Feb 20, 2024

—CM-101 Phase 2 Trial for the Treatment of Primary Sclerosing Cholangitis (PSC) Has Completed Patient Enrollment with Topline Data Expected Midyear 2024— —New CM-101 Patents Granted by...

Feb 14, 2024

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today...

All News

Stock Info
NASDAQCMMB
Events
Wednesday, April 10, 2024
10:00am EDT

Format: Virtual webcast with live Q&A
SpeakersChristopher Bowlus MD, Chief, Division of Gastroenterology & Hepatology, UC Davis Health
Massimo Pinzani, MD, PhD, UCL Professor of Medicine, Founder of the UCL Institute for Liver and Digestive Health & Science Director, ISMETT UPMC
Ricky Safer, Founder & CEO, PSC Partners Seeking a Cure

Tuesday, March 12, 2024
10:40am EDT

Date: Mar. 12, 2024
Time: 10:40 am ET
Venue: Fontainebleau Hotel
Format: Live presentation
Information: LeerinkEvents@Leerink.com

All Events

Featured Presentations

Download

Chemomab Corporate Overview - March 2024

 

Annual Report

Download

Chemomab 2022 Annual Report